Gautam Adani makes big announcement, to invest Rs 600000000000 in world-class affordable...
Gautam Adani announces healthcare sector move: In a massive step towards improving multidisciplinary healthcare ecosystem in India, Billionaire Gautam Adani on Friday revealed plans to build an AI-first, multidisciplinary healthcare ecosystem that integrates affordability, scalability, and global best practices, as he shared his vision for transforming healthcare in India.
As per a report covered by PTI news agency, Gautam Adani called for a complete system-wide redesign to meet the needs of the future while he was speaking at the 5th Annual Conference of the Society for Minimally Invasive Spine Surgery – Asia Pacific (SMISS-AP).
Adani, who heads ports-to-energy conglomerate, said three years ago, on his 60th birthday, his family pledged Rs 60,000 crore towards healthcare, education, and skill development. Why Gautam Adani is entering Healthcare sector?
'We did not enter healthcare because it lacked momentum. We entered because the momentum was not enough,' Gautam Adani said.
'The pace of change was out of step with the urgency of future demands. As the landscape unfolded, one truth stood out – healthcare does not need incremental upgrades. It needs a system-wide redesign. Not an evolution but a revolution rooted in intelligence as well as empathy.' Why Adani highlighted low back pain issue?
Gautam Adani Citing highlighted the low back pain as a leading cause of disability in India. Saying that the back pain issue is a crisis more widespread than diabetes or heart disease – he said: 'If we are to carry the full weight of our national ambition, we must first heal the spine of our people.'
Referring to the previously announced Adani Healthcare Temples – large, 1,000-bed integrated medical campuses to be established first in Ahmedabad and Mumbai – Adani said they would be 'world-class, affordable, AI-first healthcare ecosystems' and would comprise 'modular, scalable infrastructure of the kind that can expand rapidly in the face of pandemics or emergencies.'
Billionaire Adani also urged the assembled global gathering of spine surgeons and specialists to become not only medical leaders but nation-builders.
(With inputs from agencies)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Deccan Herald
2 hours ago
- Deccan Herald
BBMP's chicken rice plan for strays sparks cheers, criticism
Every day for the last six years, promptly at noon, 37-year-old 'Protein' Prabhu has sat with a basket of bananas at the entrance of the sprawling Indian Institute of Statistics campus, adjacent to the Bangalore University campus, feeding the monkeys that live in and around the area. Prabhu also feeds about 30 dogs in the vicinity, but he waits until nightfall to avoid agitating neighbours who object to feeding strays. He is happy that the Bruhat Bengaluru Mahanagara Palike (BBMP) has decided to feed chicken and rice to street dogs across all eight zones—around 4,000 in total—at an estimated cost of Rs 2.8 lakh. "This is a great step to control dog aggression, and a huge relief to people like me who spend from our own pockets. I spend about Rs 2,500 daily on chicken and rice for the dogs, and another Rs 2,000 for 50 kg of bananas that I feed to monkeys and cows," Prabhu told PTI. According to BBMP's tender document, the civic body plans to feed around 440 dogs in each zone. Each day, at about 11 am, a 400 gm meal of chicken and rice—providing roughly 750 calories—will be served at designated feeding points, it added.
Economic Times
2 hours ago
- Economic Times
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi
Synopsis Sun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for severe hair loss, leading to the dismissal of pending litigation in the US. Incyte has granted Sun a non-exclusive license for oral deuruxolitinib for specific non-oncology indications, including alopecia areata, in the US. Reuters Sun pharma logo( File photo) Sun Pharmaceutical Industries on Monday said it has inked a settlement pact with US-based Incyte Corporation regarding Leqselvi, a drug used for severe hair the terms of agreement, the parties will seek dismissal of the pending Leqselvi litigation in the US District Court for the District of New Jersey, and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation, the Mumbai-based drug major said in a statement. As a part of the agreement, Incyte has granted to Sun a limited, non-exclusive license to US Patent Nos. 9,662,335 and certain other related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications, including alopecia areata, in the US, it added. Sun will pay Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and license, it stated. Other specific terms of the settlement and license agreement are confidential, it added. In a separate statement, the drug firm announced the launch of Leqselvi (8 mg) tablets in the US medication (deuruxolitinib) is indicated for the treatment of adults with severe alopecia areata."The launch of Leqselvi in the US brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them," Richard Ascroft, CEO of Sun Pharma North America, said."As a company committed to launching new therapeutic options which address the unmet needs of patients, adding Leqselvi to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community," he added. Shares of Sun Pharma ended 0.54 per cent higher at Rs 1,681.45 apiece on the BSE.
Time of India
3 hours ago
- Time of India
Four years on, home guard's family gets Rs 25 lakh Covid relief in Gujarat
Ahmedabad: Four years after a home guard died during the Covid-19 pandemic, the state govt gave Rs 25 lakh compensation to his widow. The payment was made after the family approached the Gujarat high court, questioning the grounds on which the compensation was denied. The govt had refused to pay the compensation, claiming that the RTPCR/Rapid test result did not disclose that the home guard was suffering from coronavirus. In this case, Mahendrasinh Bhati fell ill when he was deployed for duty in the Krushnanagar police station area in April 2021, during the second wave of the pandemic. His HRCT/CT scan report indicated that he contracted Covid-19, and he was admitted to the Civil Hospital. He died on April 11, 2021, after three days of treatment. You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad When his family claimed compensation citing circulars issued by the state govt on March 31, 2020, and July 28, 2020, by which the govt announced Rs 25 lakh ex gratia for the govt employees who perished to Covid infection while performing their duty, the state govt rejected the family's claim. They stated that there was no RTPCR test result reflecting Bhati was suffering from Covid-19, and therefore the family was not entitled to compensation meant for the corona warrior's death. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like American Investor Warren Buffett Recommends: 5 Books For Turning Your Life Around Blinkist: Warren Buffett's Reading List Undo Bhati's widow, Sneha, approached the HC through advocate Ratna Vora, demanding the compensation. She questioned the grounds on which the claim was rejected. On June 26, the district commandant of Home Guards issued a communication accepting that Bhati died due to Covid-19 while performing his duty to maintain law and order, and the compensation was paid to his family from the Chief Minister's Relief Fund. Following the payment, the petition became infructuous, and the HC disposed of it.
